Tianlong Ji
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tianlong Ji has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Chen Jiang
Department of Radiation Oncology, The First Hospital of China Medical University, Shenyang, China
1 shared publication - Chengbo Ren
Department of Radiation Oncology, The First Hospital of China Medical University, 155 Nanjing Road, Heping District, Shenyang, 110001, China
1 shared publication - Fei Gu
Department of radiotherapy, The First Affiliated Hospital of China Medical University, No. 155 Nanjing North Street, Shenyang, 110001, Liaoning, China
1 shared publication Feng Cai
Department of Radiation Oncology the First Hospital of China Medical University Shenyang China
1 shared publicationGuang Li
Department of Radiation Oncology the First Hospital of China Medical University Shenyang China
1 shared publication- Guang Li
Department of Radiation Oncology, The First Hospital of China Medical University, 155 Nanjing Road, Heping District, Shenyang, 110001, China
1 shared publication
Latest Publications
- Open Access
- 9 May 2024
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 47, 100792
Application and progress of artificial intelligence in radiation therapy dose prediction
- 9 May 2024
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 47, 100792
Open AccessApplication and progress of artificial intelligence in radiation therapy dose prediction
- Open Access
- 26 July 2023
- Published by Springer Nature in Cell Death & Disease
- Vol. 14 (7) , 1-9
TIGIT, a novel immune checkpoint therapy for melanoma
Melanoma is the most aggressive and deadliest type of skin cancer. In the last 10 years, immune checkpoint blockades (ICBs) including PD-1/PD-L1 and CTLA-4 inhibitor has been shown to be effective against melanoma. PD-1/PD-L1 and CTLA-4 inhibitors have shown varying degrees of drug resistance in the treatment of melanoma patients. Furthermore, the clinical benefits of ICBs are also accompanied by severe immune toxicity. Therefore, there is an urgent need to develop new immune checkpoint inhibitors to optimize melanoma therapy and reduce cytotoxicity. T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain (TIGIT) is thought to activate inhibitory receptors in T cells, natural killer (NK) cells, and regulatory T cells (Tregs), and has become a promising target for immunotherapy. Studies have found that TIGIT can be detected in different stages of melanoma, which is closely related to the occurrence, development, and prognosis of melanoma. This review mainly describes the immunosuppressive mechanism of TIGIT and its role in antitumor immunity of melanoma, so as to provide new ideas and schemes for the clinical treatment of melanoma with targeted TIGIT.
- 26 July 2023
- Published by Springer Nature in Cell Death & Disease
- Vol. 14 (7) , 1-9
Open AccessTIGIT, a novel immune checkpoint therapy for melanoma
Melanoma is the most aggressive and deadliest type of skin cancer. In the last 10 years, immune checkpoint blockades (ICBs) including PD-1/PD-L1 and CTLA-4 inhibitor has been shown to be effective against melanoma. PD-1/PD-L1 and CTLA-4 inhibitors have shown varying degrees of drug resistance in the treatment of melanoma patients. Furthermore, the clinical benefits of ICBs are also accompanied by severe immune toxicity. Therefore, there is an urgent need to develop new immune checkpoint inhibitors to optimize melanoma therapy and reduce cytotoxicity. T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain (TIGIT) is thought to activate inhibitory receptors in T cells, natural killer (NK) cells, and regulatory T cells (Tregs), and has become a promising target for immunotherapy. Studies have found that TIGIT can be detected in different stages of melanoma, which is closely related to the occurrence, development, and prognosis of melanoma. This review mainly describes the immunosuppressive mechanism of TIGIT and its role in antitumor immunity of melanoma, so as to provide new ideas and schemes for the clinical treatment of melanoma with targeted TIGIT.
- Open Access
- 31 July 2021
- Published by Wiley in Asia-Pacific Journal of Clinical Oncology
- Vol. 18 (5) , E263-E267
Comparison between flattening filter‐free (FFF) and flattened photon beam VMAT plans for the whole brain radiotherapy (WBRT) with hippocampus sparing
Purpose: To evaluate and investigate the feasibility of flattening filter‐free (FFF) beam for the whole‐brain radiotherapy (WBRT) with hippocampus sparing.Methods: Eighteen patients with volumetric‐modulated arc therapy (VMAT) plans in FFF and conventional beam modes were included in this study. The prescribed dose was 30 Gy in 10 fractions. The conformity index (CI), heterogeneity index reported by TPS (HI‐M), and homogeneity index (HI) for planning target volume (PTV) were evaluated. Subsequently, the following parameters for PTV were calculated and compared: D2%, D98%; the mean dose, maximum dose, and minimal dose for OARs. Plan modulation index, total MUs, and the gamma index were used to evaluate the plan quality.Results: HI‐M results were similar for the two techniques (1.239 vs. 1.247, respectively, p = 0.048); FFF beam plans yielded lower D2% compared to FF beam plans (3,416.3 cGy vs. 3,437.2 cGy, p = 0.22), mean dose (3,177.5 cGy vs. 3,195.2 cGy, p = 0.009), and CI (0.884 vs. 0.876, p = 0.001) for PTV. Significant differences were observed between the two beam modes (FF model vs. FFF model) for the maximum dose (1,612.9 cGy vs. 1,470.2 cGy, respectively, p < 0.001), minimum dose (987.6 cGy vs. 898.8 cGy, respectively, p < 0.001), and the mean dose (1144.4 cGy vs. 1047.3 cGy, respectively, p < 0.001) to the hippocampus, and the maximum dose to the eyes (2,792.6 cGy vs. 2,751.3 cGy, respectively, p < 0.001). The average total MUs for FFF‐VMAT plans was significantly greater than FF‐VMAT plans. However, differences for the plan modulation index and the gamma index were negligible.Conclusion: In comparison with FF beam, the FFF beam mode offers a clear benefit with respect to WBRT with hippocampal sparing.
- 31 July 2021
- Published by Wiley in Asia-Pacific Journal of Clinical Oncology
- Vol. 18 (5) , E263-E267
Open AccessComparison between flattening filter‐free (FFF) and flattened photon beam VMAT plans for the whole brain radiotherapy (WBRT) with hippocampus sparing
Purpose: To evaluate and investigate the feasibility of flattening filter‐free (FFF) beam for the whole‐brain radiotherapy (WBRT) with hippocampus sparing.Methods: Eighteen patients with volumetric‐modulated arc therapy (VMAT) plans in FFF and conventional beam modes were included in this study. The prescribed dose was 30 Gy in 10 fractions. The conformity index (CI), heterogeneity index reported by TPS (HI‐M), and homogeneity index (HI) for planning target volume (PTV) were evaluated. Subsequently, the following parameters for PTV were calculated and compared: D2%, D98%; the mean dose, maximum dose, and minimal dose for OARs. Plan modulation index, total MUs, and the gamma index were used to evaluate the plan quality.Results: HI‐M results were similar for the two techniques (1.239 vs. 1.247, respectively, p = 0.048); FFF beam plans yielded lower D2% compared to FF beam plans (3,416.3 cGy vs. 3,437.2 cGy, p = 0.22), mean dose (3,177.5 cGy vs. 3,195.2 cGy, p = 0.009), and CI (0.884 vs. 0.876, p = 0.001) for PTV. Significant differences were observed between the two beam modes (FF model vs. FFF model) for the maximum dose (1,612.9 cGy vs. 1,470.2 cGy, respectively, p < 0.001), minimum dose (987.6 cGy vs. 898.8 cGy, respectively, p < 0.001), and the mean dose (1144.4 cGy vs. 1047.3 cGy, respectively, p < 0.001) to the hippocampus, and the maximum dose to the eyes (2,792.6 cGy vs. 2,751.3 cGy, respectively, p < 0.001). The average total MUs for FFF‐VMAT plans was significantly greater than FF‐VMAT plans. However, differences for the plan modulation index and the gamma index were negligible.Conclusion: In comparison with FF beam, the FFF beam mode offers a clear benefit with respect to WBRT with hippocampal sparing.
- Open Access
- 29 July 2020
- Published by Springer Nature in Radiation Oncology
- Vol. 15 (1) , 1-9
Pelvic bone marrow sparing intensity modulated radiotherapy reduces the incidence of the hematologic toxicity of patients with cervical cancer receiving concurrent chemoradiotherapy: a single-center prospective randomized controlled trial
Purpose: To test the efficacy and feasibility of pelvic bone marrow sparing intensity modulated radiotherapy (PBMS-IMRT) in reducing grade 2 or higher hematological toxicity (HT2+) for patients with cervical cancer treated with concurrent chemoradiotherapy. Methods and materials: A total of 164 patients with Stage Ib2–IIIb cervical cancer were prospectively enrolled from March 2018 to March 2019 at a single center and were randomly allocated into the PBMS group or the control group. The control group received weekly cisplatin concurrently with IMRT, followed by intracavitary brachytherapy. The PBMS group additionally received PBM dose constraint. The dosimetric parameters of the pelvic bone (PB) and the subsites including hip bone (HIP) and lumbosacral spine (LSS) and the corresponding bone marrow were recorded. The endpoint of the trial was acute hematologic or gastrointestinal toxicity. Receiver operating characteristic curves were used to derive optimal dosimetric planning constraints. Results: Eighty-two patients in the PBMS group and 82 in the control group were enrolled for statistical analysis. The incidence of HT2+ in the PBMS group was 50.0%, significantly lower than the 69.5% incidence in the control group (P = 0.02). Patients with PB V40 ≥ 28% were more likely to experience HT2+ (OR = 2.85, P = 0.006), while the incidence of grade 2 or higher gastrointestinal toxicity (GT2+) events did not differ significantly between the two groups (P > 0.05). Dosimetric parameters of LSS showed stronger associations with HT2+ than other subsites. The patients with LSS V10 ≥ 87% and LSS mean ≥ 39 Gy were more likely to experience HT2+ (OR = 3.13, P = 0.001;OR = 3.03, P = 0.002, respectively). Conclusion: PBMS-IMRT reduced HT compared with IMRT alone. Efforts to maintain LSS V10 < 87%, LSS mean < 39 Gy and PB V40 < 28% simultaneously may reduce the risk of HT2 +. Trial registration: The trial was registered with Chinese clinical trial registry (ChiCTR1800015069).
- 29 July 2020
- Published by Springer Nature in Radiation Oncology
- Vol. 15 (1) , 1-9
Open AccessPelvic bone marrow sparing intensity modulated radiotherapy reduces the incidence of the hematologic toxicity of patients with cervical cancer receiving concurrent chemoradiotherapy: a single-center prospective randomized controlled trial
Purpose: To test the efficacy and feasibility of pelvic bone marrow sparing intensity modulated radiotherapy (PBMS-IMRT) in reducing grade 2 or higher hematological toxicity (HT2+) for patients with cervical cancer treated with concurrent chemoradiotherapy. Methods and materials: A total of 164 patients with Stage Ib2–IIIb cervical cancer were prospectively enrolled from March 2018 to March 2019 at a single center and were randomly allocated into the PBMS group or the control group. The control group received weekly cisplatin concurrently with IMRT, followed by intracavitary brachytherapy. The PBMS group additionally received PBM dose constraint. The dosimetric parameters of the pelvic bone (PB) and the subsites including hip bone (HIP) and lumbosacral spine (LSS) and the corresponding bone marrow were recorded. The endpoint of the trial was acute hematologic or gastrointestinal toxicity. Receiver operating characteristic curves were used to derive optimal dosimetric planning constraints. Results: Eighty-two patients in the PBMS group and 82 in the control group were enrolled for statistical analysis. The incidence of HT2+ in the PBMS group was 50.0%, significantly lower than the 69.5% incidence in the control group (P = 0.02). Patients with PB V40 ≥ 28% were more likely to experience HT2+ (OR = 2.85, P = 0.006), while the incidence of grade 2 or higher gastrointestinal toxicity (GT2+) events did not differ significantly between the two groups (P > 0.05). Dosimetric parameters of LSS showed stronger associations with HT2+ than other subsites. The patients with LSS V10 ≥ 87% and LSS mean ≥ 39 Gy were more likely to experience HT2+ (OR = 3.13, P = 0.001;OR = 3.03, P = 0.002, respectively). Conclusion: PBMS-IMRT reduced HT compared with IMRT alone. Efforts to maintain LSS V10 < 87%, LSS mean < 39 Gy and PB V40 < 28% simultaneously may reduce the risk of HT2 +. Trial registration: The trial was registered with Chinese clinical trial registry (ChiCTR1800015069).
- Open Access
- 16 April 2018
- Published by Springer Nature in Radiation Oncology
- Vol. 13 (1) , 69
The risk and predictors for severe radiation pneumonitis in lung cancer patients treated with thoracic reirradiation
Thoracic reirradiation (re-RT) is increasingly administered. However, radiation pneumonitis (RP) remains to be the most common side effect from retreatment. This study aimed to determine the risk and predictors for severe RP in patients receiving thoracic re-RT. Sixty seven patients with lung cancer received thoracic re-RT for recurrent or metastatic disease. Three-dimensional conformal radiotherapy (3D-CRT)/intensity modulated radiotherapy (IMRT) was used for 60 patients, and stereotactic body radiation therapy (SBRT) was used in 7 patients. Deformable image registration (DIR) was performed to create a composite plan. Severe (grade ≥ 3) RP was graded according to Common Terminology Criteria for Adverse Events version 4.0. Eighteen patients (26.9%) developed grade ≥ 3 RP (17 of grade 3, and 1 of grade 4). In univariate analyses, V5 and mean lung dose (MLD) of initial RT or re-RT plans, V5 and V20 of composite plans, and the overlap between V5 of initial RT and V5 of re-RT plans/V5 of re-RT plans (overlap-V5/re-V5) were significantly associated with grade ≥ 3 RP (P < 0.05 for each comparison). Multivariate analysis revealed that MLD of the initial RT plans (HR = 14.515, 95%CI:1.778–118.494, P = 0.013), V5 of the composite plans (HR = 7.398, 95%CI:1.319–41.495, P = 0.023), and overlap-V5/re-V5 (P = 0.041) were independent predictors for grade ≥ 3 RP. Out-of-field failures with medium overlap-V5/re-V5 of 0.4–0.8 was associated with higher risk of grade ≥ 3 RP compared with in-field failures (18.3% vs. 50%, P = 0.014). The risk of grade ≥ 3 RP could be predicted not only by dose-volume variables from re-RT plan, but also by some from initial-RT and composite plans. Out-of-field failures was associated with higher risk of severe RP compared with in-field failures in some cases.
- 16 April 2018
- Published by Springer Nature in Radiation Oncology
- Vol. 13 (1) , 69
Open AccessThe risk and predictors for severe radiation pneumonitis in lung cancer patients treated with thoracic reirradiation
Thoracic reirradiation (re-RT) is increasingly administered. However, radiation pneumonitis (RP) remains to be the most common side effect from retreatment. This study aimed to determine the risk and predictors for severe RP in patients receiving thoracic re-RT. Sixty seven patients with lung cancer received thoracic re-RT for recurrent or metastatic disease. Three-dimensional conformal radiotherapy (3D-CRT)/intensity modulated radiotherapy (IMRT) was used for 60 patients, and stereotactic body radiation therapy (SBRT) was used in 7 patients. Deformable image registration (DIR) was performed to create a composite plan. Severe (grade ≥ 3) RP was graded according to Common Terminology Criteria for Adverse Events version 4.0. Eighteen patients (26.9%) developed grade ≥ 3 RP (17 of grade 3, and 1 of grade 4). In univariate analyses, V5 and mean lung dose (MLD) of initial RT or re-RT plans, V5 and V20 of composite plans, and the overlap between V5 of initial RT and V5 of re-RT plans/V5 of re-RT plans (overlap-V5/re-V5) were significantly associated with grade ≥ 3 RP (P < 0.05 for each comparison). Multivariate analysis revealed that MLD of the initial RT plans (HR = 14.515, 95%CI:1.778–118.494, P = 0.013), V5 of the composite plans (HR = 7.398, 95%CI:1.319–41.495, P = 0.023), and overlap-V5/re-V5 (P = 0.041) were independent predictors for grade ≥ 3 RP. Out-of-field failures with medium overlap-V5/re-V5 of 0.4–0.8 was associated with higher risk of grade ≥ 3 RP compared with in-field failures (18.3% vs. 50%, P = 0.014). The risk of grade ≥ 3 RP could be predicted not only by dose-volume variables from re-RT plan, but also by some from initial-RT and composite plans. Out-of-field failures was associated with higher risk of severe RP compared with in-field failures in some cases.